FDA green light for first GA therapy, Apellis' Syfovre

18 February 2023
apellis_big

The US Food and Drug Administration (FDA) on Friday approved retinal disease specialist Apellis Pharmaceuticals' (Nasdaq: APLS) drug for geographic atrophy secondary to age-related macular degeneration (AMD) after pushing back its planned decision by three months to review more data.

Under the trade name Syfovre, pegcetacoplan injection becomes the first and only FDA-approved treatment for GA, a leading cause of blindness that impacts more than one million people in the USA and five million people worldwide.

Apellis shares closed up almost 7%, and rose a further 9.3% to $60.67 in after-hours trading.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology